SteelPeak Wealth’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

SteelPeak Wealth’s Portfolio EVFM Stock Details EVFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,000	Closed	-$5K	–	499
2022 Q1	$5K	Sell	1,000 -1,000	-50%	-$6.29K	﹤0.01%	431
2021 Q4	$11K	Sell	2,000 -2,000	-50%	-$17K	﹤0.01%	412
2021 Q3	$44K	Buy	+4,000	New	+$50.3K	﹤0.01%	418

Other funds holding EVFM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

FWSM

First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SteelPeak Wealth's EVFM Position: Q2 2022 in Review

SteelPeak Wealth sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2022, closing a stake of 1,000 shares — an estimated $5K sold.

SteelPeak Wealth first reported a position in EVFM in Q3 2021 and held it in 3 quarters. The position peaked at $44K in Q3 2021. 44 funds tracked by Wall St. Rank hold EVFM as of Q2 2022.

SteelPeak Wealth reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
SteelPeak Wealth sold 1,000 Evofem Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $5K.
SteelPeak Wealth first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
SteelPeak Wealth's Evofem Biosciences, Inc. Common Stock position peaked at $44K in Q3 2021.
44 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2022.

Based on SteelPeak Wealth's 13F filing for Q2 2022, filed 2 Aug 2022.